mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer
Tomohiro Tamura(Keio University), Osamu Nagano(Fujita Health University), Ahmed A. Ahmed(St. George's University), Daisuke Aoki(International University of Health and Welfare), Kouji Banno(Keio University), Wataru Yamagami(Keio University), Tatsuyuki Chiyoda(Keio University), Iori Kisu(Fujita Health University), Hideyuki Saya(Fujita Health University Hospital), Yusuke Kobayashi(University of Tsukuba), Eiji Sugihara(Fujita Health University), Hiroyuki Nobusue(Nihon University), Yuji Otsuki(Fujita Health University), Kazuhiro Sakurada(Keio University), Tomoko Akahane(Keio University), Kenta Masuda(Keio University), Hajime Okita(Keio University Hospital), Keiyo Imaeda(Keio University), Juntaro Yamasaki(Fujita Health University), Kentaro Suina(Juntendo University), Shimpei Nagai(Obayashi (Japan)), Miho Kawaida(Keio University)
Cited by 5
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Driver mutations in <i>TP53</i> are ubiquitous in high grade serous carcinoma of the ovary
|The Journal of Pathology|2010|836
Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell
|Nature Communications|2012|382